William Blair Issues Optimistic Forecast for PTCT Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Research analysts at William Blair upped their Q1 2025 EPS estimates for PTC Therapeutics in a research report issued on Wednesday, May 7th. William Blair analyst S. Corwin now forecasts that the biopharmaceutical company will post earnings per share of $10.04 for the quarter, up from their prior forecast of ($0.83). The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share. William Blair also issued estimates for PTC Therapeutics’ Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.36) EPS, Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at $6.47 EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($2.79) EPS.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $9.19. The business had revenue of $1.18 billion during the quarter, compared to analyst estimates of $437.16 million. During the same quarter in the previous year, the firm posted ($1.20) earnings per share. The firm’s quarterly revenue was down 9.6% on a year-over-year basis.

Other research analysts have also issued research reports about the company. Barclays lowered their price target on PTC Therapeutics from $56.00 to $42.00 and set an “equal weight” rating on the stock in a research report on Thursday. StockNews.com raised shares of PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Morgan Stanley reissued an “overweight” rating and issued a $70.00 price objective (up previously from $67.00) on shares of PTC Therapeutics in a research report on Friday, March 7th. Robert W. Baird dropped their target price on shares of PTC Therapeutics from $70.00 to $66.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Royal Bank of Canada lifted their price target on PTC Therapeutics from $57.00 to $58.00 and gave the stock an “outperform” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $61.92.

PTC Therapeutics Stock Performance

NASDAQ:PTCT opened at $44.23 on Friday. The stock’s 50-day simple moving average is $48.86 and its 200 day simple moving average is $47.02. PTC Therapeutics has a 52-week low of $28.72 and a 52-week high of $58.38. The company has a market cap of $3.50 billion, a P/E ratio of -7.45 and a beta of 0.52.

Insiders Place Their Bets

In other PTC Therapeutics news, CAO Christine Marie Utter sold 879 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total transaction of $44,037.90. Following the transaction, the chief accounting officer now owns 63,442 shares in the company, valued at $3,178,444.20. This trade represents a 1.37 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Mark Elliott Boulding sold 1,333 shares of PTC Therapeutics stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total value of $66,783.30. Following the completion of the transaction, the vice president now directly owns 105,515 shares of the company’s stock, valued at $5,286,301.50. This represents a 1.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,305 shares of company stock worth $1,682,755 in the last 90 days. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PTCT. Toronto Dominion Bank bought a new position in PTC Therapeutics in the 4th quarter valued at about $148,363,000. Driehaus Capital Management LLC acquired a new position in PTC Therapeutics during the fourth quarter valued at approximately $46,993,000. Point72 Asset Management L.P. lifted its stake in PTC Therapeutics by 150.6% during the fourth quarter. Point72 Asset Management L.P. now owns 1,443,362 shares of the biopharmaceutical company’s stock worth $65,153,000 after purchasing an additional 867,502 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of PTC Therapeutics by 24.4% in the 4th quarter. Janus Henderson Group PLC now owns 2,325,915 shares of the biopharmaceutical company’s stock valued at $105,015,000 after purchasing an additional 455,698 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its stake in shares of PTC Therapeutics by 107.4% in the 4th quarter. Pictet Asset Management Holding SA now owns 736,388 shares of the biopharmaceutical company’s stock valued at $33,241,000 after purchasing an additional 381,319 shares during the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.